Alimera Sciences announces that its distribution partner, Horus Pharma S.A.S. through its Swiss affiliate Horus Pharma Suisse SA, has filed a marketing authorization application, MAA, dossier for ILUVIEN for diabetic macular edema, DME, with the Swiss Agency for Therapeutic Products. "In our continued efforts for expanding our distribution, the partnership with Horus in Switzerland takes this critical first step toward an approval there," said Rick Eiswirth, President and Chief Executive Officer of Alimera. "Horus Pharma has been a close partner for us, with proven success selling ILUVIEN in other European markets, and has worked very quickly with our team to develop this dossier."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALIM:
